Analysts expect bioAffinity Technologies, Inc. to report revenue of 1.77 M for Q2 26, against a range of 1.61 M to 1.93 M. The most recent reported quarter, Q1 26, came in at 1.35 M, a 11.1% miss against the 1.52 M consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 2.40 M | 2.35 M | 2.20 M | 1.85 M | 1.27 M | 1.45 M | 1.59 M | 1.35 M | - | - | - | - | - | - | - |
| High Estimate | 2.74 M | 2.54 M | 2.41 M | 2.29 M | 1.62 M | 1.43 M | 1.78 M | 1.66 M | 1.93 M | 1.96 M | 2.23 M | 1.43 M | 1.51 M | 1.96 M | 2.36 M |
| Low Estimate | 2.36 M | 2.21 M | 2.09 M | 2.11 M | 1.52 M | 1.22 M | 1.53 M | 1.37 M | 1.61 M | 1.67 M | 1.95 M | 1.33 M | 1.33 M | 1.69 M | 2.15 M |
| Consensus Estimate | 2.55 M | 2.38 M | 2.25 M | 2.20 M | 1.57 M | 1.33 M | 1.66 M | 1.52 M | 1.77 M | 1.81 M | 2.09 M | 1.38 M | 1.42 M | 1.83 M | 2.25 M |
Analysts expect bioAffinity Technologies, Inc. to report earnings per share of -2.02 for Q2 26, against a range of -2.18 to -1.86. The most recent reported quarter, Q1 26, came in at -0.81, a 64.3% beat against the -2.27 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -5.70 | -4.80 | -5.70 | -4.80 | -5.10 | -4.74 | 5.98 | -0.81 | - | - | - | - | - | - | - |
| High Estimate | -5.04 | -4.23 | -3.72 | -4.49 | -2.64 | -2.78 | -2.67 | -2.05 | -1.86 | -2.09 | -1.67 | 0.01 | -0.47 | -0.45 | 1.28 |
| Low Estimate | -5.54 | -5.15 | -4.22 | -4.89 | -2.96 | -2.98 | -2.97 | -2.49 | -2.18 | -2.35 | -1.83 | 0.01 | -0.57 | -0.53 | 1.08 |
| Consensus Estimate | -5.29 | -4.69 | -3.97 | -4.69 | -2.80 | -2.88 | -2.82 | -2.27 | -2.02 | -2.22 | -1.75 | 0.01 | -0.52 | -0.49 | 1.18 |